Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients-Reference-Cited by-同舟云学术

Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients

Published:2017-01-11 Issue:4 Volume:8 Page:383-392
ISSN:2165-5979
Container-title:Bioengineered
language:en
Short-container-title:Bioengineered

Author:

Ding Li¹,Zhang Zijin¹,Xu Yan¹,Zhang Yongqiang¹

Affiliation:

1. Department of Oncology, Beijing Hospital, National Center of Gerontology, Beijing, China

Publisher

Informa UK Limited

Subject

Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21655979.2016.1235101

Reference66 articles.

1. The footprints of cancer development: Cancer biomarkers

2. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

3. A Clinical Database of Breast Cancer Patients Reveals Distinctive Clinico-pathological Characteristics: a Study From Central China

4. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nomogram based on combining clinical features and contrast enhanced ultrasound is not able to identify Her-2 over-expressing cancer from other breast cancers;Frontiers in Oncology;2023-01-26

2. The role of p53 and ki67 in predicting clinical outcome in breast cancer patients;Journal of Cancer Research and Therapeutics;2023

3. An observational study of association of clinicopathological stage and Ki-67, P53, human epidermal growth factor receptor 2/neu, estrogen receptor, and progesterone receptor status in breast cancer;Journal of Radiation and Cancer Research;2023

4. A comparison of Chinese multicenter breast cancer database and SEER database;Scientific Reports;2022-06-21

5. CCDC106 promotes the proliferation and invasion of ovarian cancer cells by suppressing p21 transcription through a p53-independent pathway;Bioengineered;2022-04-01